SCHEMBL6491963

SCHEMBL6491963

CCc1cc(CC)cc(CC(=O)O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 6/20 0.50
CA2 P00918 1/20 0.50
CAMK2A Q9UQM7 1/20 0.50
RXRA P19793 2/20 0.48
RXRB P28702 1/20 0.48
AKR1B1 P15121 1/20 0.48
ALDH1A1 P00352 5/20 0.47
HPGD P15428 4/20 0.47
HSD17B10 Q99714 4/20 0.47
THRA P10827 5/20 0.46
KDM4E B2RXH2 3/20 0.45
TSHR P16473 3/20 0.45
GAA P10253 3/20 0.45
MAPT P10636 2/20 0.45
LMNA P02545 2/20 0.45
RGS12 O14924 1/20 0.45
POLB P06746 1/20 0.45
NFKB1 P19838 1/20 0.45
APEX1 P27695 1/20 0.45
THPO P40225 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14143941 0.91 THRB (0.44) THRBCA2CAMK2ARXRARXRB
SCHEMBL10241639 0.89 THRB (0.43) THRBCA2CAMK2ARXRARXRB
SCHEMBL583915 0.87 AKR1B1 (0.60) THRBCA2CAMK2ARXRAAKR1B1
SCHEMBL22773948 0.84 RXRA (0.54) THRBRXRARXRBALDH1A1LMNA
SCHEMBL29467110 0.84 RXRA (0.54) THRBRXRARXRBALDH1A1LMNA
SCHEMBL1515871 0.82 AKR1B1 (0.58) AKR1B1ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL31119235 0.82 PTGS2 (0.60) RXRARXRBAKR1B1ALDH1A1HPGD
Acetic Acid SCHEMBL27852475 0.81 RXRA (0.54) RXRARXRBALDH1A1GAAAKR1C3
SCHEMBL156207 0.80 ALDH1A1 (0.63) CA2CAMK2ARXRARXRBAKR1B1
SCHEMBL13438518 0.80 AKR1B1 (0.48) THRBCA2CAMK2ARXRAAKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951940-B2 Piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2005-10-04 US disclosed
US-20040072840-A1 Novel piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2004-04-15 US disclosed
US-6642233-B1 Strong affinity and high selectivity for the human NK1 receptors of substance P. SANOFI-SYNTHELABO (FR) 2003-11-04 US disclosed
US-6506750-B1 N-(phenylacetyl)morpholine derivatives useful as NK1 receptor antagonists, a process for the preparation thereof, and pharmaceutical compositions containing them as active principle. SANOFI-SYNTHELABO (FR) 2003-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072840-A1 Novel piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them TACR1, TACR2, KCNJ11 THRB 3070/4885CA2 635/4885CAMK2A 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.